Royal Bank Of Canada Myovant Sciences Ltd. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$24.03 - $27.02 $34,362 - $38,638	-1,430 Reduced 36.8%	2,456 $66,000
Q3 2022 Nov 14, 2022	SELL	$11.6 - $20.44 $603,490 - $1.06 Million	-52,025 Reduced 93.05%	3,886 $70,000
Q2 2022 Aug 15, 2022	SELL	$7.78 - $14.69 $486,841 - $919,241	-62,576 Reduced 52.81%	55,911 $695,000
Q1 2022 May 16, 2022	SELL	$11.38 - $16.4 $484,048 - $697,573	-42,535 Reduced 26.42%	118,487 $1.58 Million
Q4 2021 Feb 14, 2022	BUY	$14.31 - $23.87 $97,150 - $162,053	6,789 Added 4.4%	161,022 $2.51 Million
Q3 2021 Nov 15, 2021	BUY	$18.94 - $26.99 $2.89 Million - $4.11 Million	152,453 Added 8564.78%	154,233 $3.46 Million
Q2 2021 Aug 16, 2021	BUY	$17.07 - $24.56 $30,384 - $43,716	1,780 New	1,780 $41,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.